Thus, immune monitoring in sepsis is needed for the use of MGMT inhibitors, and down-regulated HLA-DR and lower inflammatory cytokines might be a contraindication because the overwhelming inhibition might escalate infection susceptibility. The gene discussed is MGMT; the disease is infection.